RP-HPLC Method Development and Validation for the Quantitative Determination of Ruxolitinib in Pure Form and Marketed Pharmaceutical Dosage Form
Authors
Article Information
Publication Timeline
- Published
Abstract
A novel, simple, accurate, precise, sensitive and specific analytical RP-HPLC method was developed and validated for the quantitative estimation of Ruxolitinib in bulk drugs and pharmaceutical dosage form. Chromatographic separation was achieved on an Symmetry ODS C18 (4.6×250mm, 5µm) analytical column using mobile phase composition of methanol and Phosphate Buffer in ratio of (35: 65 v/v) that was set at a flow rate of 1.0μl/min with detection of 235 nm. The retention time of Ruxolitinib was found to be 3.006min. The drug was analyzed by following the guidelines of International conference on Harmonization (ICH). This drug showing linearity in the concentration range of 6-14µg/ml and the correlation coefficient showing R2 = 0.9996. The % Recoveries showing within the limits. The presentation of the method was validated according to the present ICH guidelines for accuracy, precision and robustness, Linearity, limit of quantification, limit of detection linearity.
How to Cite
Prathusha, J., Ramakrishna, U., Poojitha, K., Amulya, K., & Radhikareddy, N. (2024). RP-HPLC Method Development and Validation for the Quantitative Determination of Ruxolitinib in Pure Form and Marketed Pharmaceutical Dosage Form. International Journal of Medical and All Body Health Research, 5(2), 15-21.
Prathusha, J, et al. "RP-HPLC Method Development and Validation for the Quantitative Determination of Ruxolitinib in Pure Form and Marketed Pharmaceutical Dosage Form." International Journal of Medical and All Body Health Research, vol. 5, no. 2, 2024, pp. 15-21.
Prathusha, J., Ramakrishna, U., Poojitha, K., Amulya, K. and Radhikareddy, N. (2024) 'RP-HPLC Method Development and Validation for the Quantitative Determination of Ruxolitinib in Pure Form and Marketed Pharmaceutical Dosage Form', International Journal of Medical and All Body Health Research, 5(2), pp. 15-21.
Prathusha J, Ramakrishna U, Poojitha K, Amulya K, Radhikareddy N. RP-HPLC Method Development and Validation for the Quantitative Determination of Ruxolitinib in Pure Form and Marketed Pharmaceutical Dosage Form. International Journal of Medical and All Body Health Research. 2024;5(2):15-21.
Similar Articles
- Formulation and evaluation of metoprolol tartrate transdermal drug patches Vol 5, Issue 2 (2024)
- Formulation and evaluation of gastroretentive floating microspheres of nimodipine Vol 5, Issue 2 (2024)
- Ntoum: A major focus of malaria in Gabon's Estuary province Vol 5, Issue 2 (2024)
- A new analytical novel RP-HPLC method development and validation for the quantitative determination of Dasatinib in pure form and marketed pharmaceutical dosage form Vol 5, Issue 2 (2024)
- Effect of Vitamin E V/S Vitamin C application on wound healing in the gingival depigmentation procedure: A split-mouth clinical comparative study Vol 5, Issue 2 (2024)
Find this Article on
Google Scholar Semantic Scholar OpenAlex ResearchGate BASEA newly published article may take a few days to appear on these services.